CAJ | 학술논문

目的：分析乳腺癌患者血清人表皮生长因子受体-2（HER-2/neu）的水平与组织HER-2表达水平的差异，分析血清HER-2/neu的影响因素以及与化疗疗效的相关性。方法采用酶联免疫吸附（ELISA）方法检测37例可手术的早期乳腺癌患者及74例晚期转移性乳腺癌患者血清HER-2/neu的水平，分析血清HER-2/neu与组织中HER-2的表达、临床参数的相关性。结果晚期乳腺癌患者血清HER-2/neu的水平与组织HER-2的状态一致性较好（P<0.05），早期乳腺癌患者中两者则无明显关系。乳腺癌血清HER-2的水平与血清CA153、CEA均无明显相关性。晚期乳腺癌血清HER-2的水平与肿瘤大小、远处转移数目、脉管瘤栓具有明显关系，而与月经状况、ER、PR均无明显关系（P>0.05）。血清HER-2水平的变化与化疗疗效有关（P<0.05）。结论晚期乳腺癌患者血清HER-2/neu水平与肿瘤组织中HER-2表达是一致的且与肿瘤负荷密切相关，可作为组织学检测的重要补充方法。
목적：분석유선암환자혈청인표피생장인자수체-2（HER-2/neu）적수평여조직HER-2표체수평적차이，분석혈청HER-2/neu적영향인소이급여화료료효적상관성。방법채용매련면역흡부（ELISA）방법검측37례가수술적조기유선암환자급74례만기전이성유선암환자혈청HER-2/neu적수평，분석혈청HER-2/neu여조직중HER-2적표체、림상삼수적상관성。결과만기유선암환자혈청HER-2/neu적수평여조직HER-2적상태일치성교호（P<0.05），조기유선암환자중량자칙무명현관계。유선암혈청HER-2적수평여혈청CA153、CEA균무명현상관성。만기유선암혈청HER-2적수평여종류대소、원처전이수목、맥관류전구유명현관계，이여월경상황、ER、PR균무명현관계（P>0.05）。혈청HER-2수평적변화여화료료효유관（P<0.05）。결론만기유선암환자혈청HER-2/neu수평여종류조직중HER-2표체시일치적차여종류부하밀절상관，가작위조직학검측적중요보충방법。
ObjectiveTo compare serum HER-2/neu protein level with tissue HER-2 status in patients with breast cancer,and to analyze influencing factor of serum HER-2/neu and the relationship between the serum HER-2/neu level and response of chemotherapy. MethodsThe serum HER-2/neu protein levels of 37 primary breast cancer and 74 metastatic breast cancer patients were detected with enzyme-linked immunosorbent assay(ELISA). The relationship between the HER-2/neu level and the clinical pathological parameters of patients,therapeutic response were analyzed.ResultsIn advanced breast cancer,the level of serum HER-2/neu was concordance with strong expression of HER-2 in tumor tissue(P<0.05). There was no significantly correlated between the level of HER-2/neu with the levels of CA153,CEA in all breast cancer patients. The serum HER2/neu level was associated with tumor size,the number of metastasis and cancer embolus(P<0.05).The change of serum HER2/neu level was associated with the response of chemotherapy (P<0.05).ConclusionSerum HER-2/neu level correlate with HER-2 overexpression of corresponding primary tumors in advanced breast cancer,and can be used as an alternative to tissue HER-2 status.